Community curated by people like you

Introbio stories

Oct 5, 2026

Shionogi to acquire IntraBio for $2 billion

Japanese pharmaceutical company Shionogi has agreed to acquire American biotech IntraBio for $2 billion, gaining global rights to Aqneursa, a treatment for rare neurological conditions.

Oct 5, 2026·3 sources

00

Top claims

▪Under Shionogi's deal to acquire IntraBio, Shionogi will turn IntraBio into a wholly owned subsidiary of Shionogi's New Jersey-headquartered U.S. division
▪Shionogi's U.S. portfolio includes the COVID-19 medicine Xocova and a treatment for complicated urinary tract and hospital-acquired respiratory infections
▪Private commercialization of university-developed drugs is necessary to bring them to market

Topics

Drug development Neurological disorders

Related entities

United States Japan